Nurix Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD from Q2 2021 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Nurix Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and growth rate from Q2 2021 to Q3 2023.
  • Nurix Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending August 31, 2023 was $2M.
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 $2M Aug 31, 2023 10-Q 2023-10-12
Q4 2022 $0 Nov 30, 2022 10-Q 2023-10-12
Q2 2021 $2.54M May 31, 2021 10-Q 2021-07-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.